{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:24:57Z","timestamp":1774329897185,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinthera.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:09:34Z","timestamp":1724472574000},"page":"799-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Raloxifene Treatment on Apolipoproteins and Lipoprotein(a) Concentrations in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"46","author":[{"given":"Xinyi","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hern\u00e1ndez-Wolters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousalya","family":"Prabahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-4405","authenticated-orcid":false,"given":"Hamed","family":"Kord-Varkaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2024.07.008_bib0001","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.4103\/0019-5545.161483","article-title":"Postmenopausal syndrome","volume":"57","author":"Dalal","year":"2015","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0002","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/GME.0000000000001532","article-title":"Lipid profile changes during the menopausal transition","volume":"27","author":"Inaraja","year":"2020","journal-title":"Menopause (New York, NY)"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.maturitas.2019.09.005","article-title":"Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"130","author":"Fonseca","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2022.111709","article-title":"The effect of vitamin D on the lipid profile as a risk factor for coronary heart disease in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials","volume":"161","author":"Zhang","year":"2022","journal-title":"Experimental gerontology"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0005","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/nu12010202","article-title":"Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women","volume":"12","author":"Ko","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0007","first-page":"1","article-title":"The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy","volume":"8","author":"Iorga","year":"2017","journal-title":"Biol Sex Diff"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0008","article-title":"The effect of 17\u03b2-estradiol plus norethisterone acetate treatment on lipoprotein (a), atherogenic and anti-atherogenic apolipoproteins levels in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"172","author":"Tang","year":"2022","journal-title":"Experim Gerontol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejogrb.2023.10.020","article-title":"The effect of tibolone treatment on apolipoproteins and lipoprotein (a) concentrations in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"292","author":"Li","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCRESAHA.120.317362","article-title":"Gut microbiota-associated activation of TLR5 induces apolipoprotein A1 production in the liver","volume":"127","author":"Yiu","year":"2020","journal-title":"Circulat Res"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0012","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Collaboration","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo (a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo (a)[S]","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cis.2014.01.009","article-title":"Anionic biopolyelectrolytes of the syndecan\/perlecan superfamily: physicochemical properties and medical significance","volume":"205","author":"Siegel","year":"2014","journal-title":"Adv Coll Interf Sci"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.ATV.0000229218.97976.43","article-title":"Scavenger receptors in atherosclerosis: beyond lipid uptake","volume":"26","author":"Moore","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein (a) and its role in inflammation, atherosclerosis and malignancies","volume":"12","author":"Ors\u00f3","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0017","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"28","author":"Martinkovich","year":"2014","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105512","article-title":"Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: a meta-analysis of randomized controlled trials","volume":"166","author":"Yang","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0019","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-5122(01)00280-8","article-title":"A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein (a) and homocysteine","volume":"41","author":"Smolders","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0021","first-page":"125","article-title":"The effects of raloxifene on serum lipid profiles, C-reactive protein and homocysteine levels in postmenopausal women","volume":"7","author":"Turan","year":"2006","journal-title":"J Turk German Gynecol Assoc"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0022","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.metabol.2005.02.010","article-title":"Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia","volume":"54","author":"Insull","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0023","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0024","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Physical Ther"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0026","first-page":"366","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0027","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"1437","article-title":"Analysing data and undertaking meta\u2010analyses","volume":"28","author":"Deeks","year":"2019"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0028","unstructured":"Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. 5. Available from www.handbook.cochrane.org.HJ."},{"key":"10.1016\/j.clinthera.2024.07.008_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0030","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"569","article-title":"Including variants on randomized trials","author":"Higgins","year":"2019"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0031","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controll Clin Trials"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0033","first-page":"125","article-title":"The effects of raloxifene on serum lipid profiles, C-reactive protein and homocysteine levels in postmenopausal women","volume":"7","author":"Turan","year":"2006","journal-title":"J Turk German Gynecol Assoc"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0034","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause (New York, NY)"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.metabol.2005.02.010","article-title":"Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia","volume":"54","author":"Insull","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0036","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF03347261","article-title":"Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women","volume":"28","author":"Francucci","year":"2005","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0037","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.fertnstert.2004.05.093","article-title":"HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women","volume":"82","author":"Vogelvang","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0038","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archinte.164.8.871","article-title":"A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women","volume":"164","author":"Reid","year":"2004","journal-title":"Arch Internal Med"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0039","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/09513590410001715207","article-title":"Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women","volume":"18","author":"Christodoulakos","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0735-1097(03)00776-9","article-title":"Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease","volume":"42","author":"Griffiths","year":"2003","journal-title":"J Am College Cardiol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0041","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-5122(01)00280-8","article-title":"A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine","volume":"41","author":"Smolders","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0042","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jcem.87.1.8168","article-title":"Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial","volume":"87","author":"Andersson","year":"2002","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0043","first-page":"134","article-title":"Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens","volume":"6","author":"Mijatovic","year":"1999","journal-title":"Menopause"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0021-9150(86)90065-1","article-title":"Is the ratio of apo B\/apo AI an early predictor of coronary atherosclerosis?","volume":"62","author":"Van Stiphout","year":"1986","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0046","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein AI, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0047","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0021-9150(97)00312-2","article-title":"Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes","volume":"137","author":"Phillips","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0048","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0009-9120(92)80004-Z","article-title":"Observed relationship between ratios HDL-cholesterol\/total cholesterol and apolipoprotein A1\/apolipoprotein B","volume":"25","author":"Kuyl","year":"1992","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0049","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1373\/clinchem.2004.038026","article-title":"Lipid disorders and mutations in the APOB gene","volume":"50","author":"Whitfield","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0050","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/metabo11100690","article-title":"Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target","volume":"11","author":"Behbodikhah","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0051","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2796.2003.01276.x","article-title":"Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy","volume":"255","author":"Walldius","year":"2004","journal-title":"J Internal Med"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0052","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.ATV.0000035521.22199.C7","article-title":"Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men","volume":"22","author":"Talmud","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0053","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.3390\/ijerph20186721","article-title":"Lipoprotein (a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives","volume":"20","author":"Vinci","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0054","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00042192-199906020-00010","article-title":"Raloxifene lowers serum lipoprotein (A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens","volume":"6","author":"Mijatovic","year":"1999","journal-title":"Menopause (New York, NY)"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10557-017-6721-6","article-title":"Raloxifene lowers plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"31","author":"Ferretti","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0056","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12020-022-03287-2","article-title":"Impact of anti-oestrogen therapy on lipoprotein(a) in postmenopausal women: a systematic review and meta-analysis of double-blind placebo-controlled clinical studies","volume":"80","author":"Fogacci","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0057","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.07.008_bib0058","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jcem.87.1.8168","article-title":"Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial","volume":"87","author":"Andersson","year":"2002","journal-title":"J Clin Endocrinol Metabol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400208X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400208X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T02:50:39Z","timestamp":1730343039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182400208X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S014929182400208X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Raloxifene Treatment on Apolipoproteins and Lipoprotein(a) Concentrations in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}